Mimotopes of the hepatitis C virus hypervariable region 1, but not the natural sequences, induce cross-reactive antibody response by genetic immunization

Hepatology

Volumn 33, Issue 3, 2001, Pages 692-703

  Zucchelli, Silvia ^a   Roccasecca, RosaMaria ^a   Meola, Annalisa ^a   Ercole, Bruno Bruni ^a   Tafi, Rosalba ^a   Dubuisson, Jean ^b   Galfré, Giovanni ^a   Cortese, Riccardo ^a   Nicosia, Alfredo ^a  

^a IRBM   (Italy)

^b INSTITUT PASTEUR DE LILLE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; GLYCOPROTEIN; HEPATITIS C VACCINE; INTERFERON; NEUTRALIZING ANTIBODY; PLASMID VECTOR; POLYPROTEIN; RIBAVIRIN;

ANTIBODY RESPONSE; ANTIGEN ANTIBODY COMPLEX; ANTIGEN EXPRESSION; ARTICLE; CELL CULTURE; CHIMERA; CHIMPANZEE; CROSS REACTION; ENZYME LINKED IMMUNOSORBENT ASSAY; HELPER CELL; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; INOCULATION; LIVER CIRRHOSIS; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SEQUENCE ANALYSIS; STIMULUS RESPONSE; VACCINATION; WESTERN BLOTTING;

EID: 0035126891     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1053/jhep.2001.22175     Document Type: Article

References (63)

1. Isolation of a cDNA clone derived from blood-borne non-A, non-B viral hepatitis genome
2. To C or not to C: These are the questions
3. Therapy of hepatitis C
4. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group
5. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International hepatitis interventional therapy group
6. Vaccination of chimpanzees against infection by the hepatitis C virus
7. Prospects for prophylactic and therapeutic C virus vaccines
8. Development of an HCV vaccine
9. Binding of hepatitis C virus to CD81
10. Perspectives for a hepatitis C virus vaccine
11. Variable and hypervariable domains are found in the regions of HCV corresponding to the flavivirus envelope and NS1 proteins and the pestivirus envelope glycoproteins
12. Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: Quasi species nature of HCV genome distribution
13. Dynamic behavior of hepatitis C virus quasi species in patients undergoing orthotopic liver transplantation
14. Evolution and selection of hepatitis C virus variants in patients with chronic hepatitis C
15. Genetic heterogeneity of hepatitis C virus: Quasi species and genotypes
16. Evidence for immune selection of hepatitis C virus (HCV) putative envelope glycoprotein variants: Potential role in chronic HCV infections
17. Humoral immune response to hypervariable region 1 of the putative envelope glycoprotein (gp70) of hepatitis C virus
18. Influence of antibodies to the hypervariable region of E2/NS1 glycoprotein on the selective replication of hepatitis C virus in chimpanzees
19. Neutralizing antibodies against hepatitis C virus and the emergence of neutralization escape mutant viruses
20. Sequence evolution of the hypervariable region in the putative envelope region E2/NS1 of hepatitis C virus is correlated with specific humoral immune responses
21. Persistent hepatitis C virus infection in a chimpanzee is associated with emergence of a cytotoxic T lymphocyte escape variant
22. Long-term evolution of the hypervariable region of hepatitis C virus in a common-source-infected cohort
23. The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies
24. Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein
25. Towards a solution for hepatitis C virus hypervariability: Mimotopes of the hypervariable region i can induce antibodies cross-reacting with a large number of viral variants
26. Application of the continuous-flow polyamide method to the solid-phase synthesis of a multiple antigen peptide (MAP) based on the sequence of a malaria epitope
27. Immunization with DNA
28. Immunization against viral proteins with naked DNA
29. Overview of DNA Vaccines
30. Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients
31. Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine
32. Heterologous protection against influenza by injection of DNA encoding a viral protein
33. Protection against malaria by immunization with plasmid DNA encoding circumsporozoite protein
34. Immunogenicity and protective efficacy of a tuberculosis DNA vaccine
35. Protection of chimpanzees from high-dose heterologous HIV-1 challenge by DNA vaccination
36. DNA vaccine for hepatitis B: Evidence for immunogenicity in chimpanzees and comparison with other vaccines
37. DNA vaccination for the induction of immune responses against hepatitis C virus proteins
38. Immunization with plasmid DNA encoding hepatitis C virus envelope E2 antigenic domains induces antibodies whose immune reactivity is linked to the injection mode
39. A specific antibody response to HCV E2 elicited in mice by intramuscular inoculation of plasmid DNA containing coding sequences for E2
40. Hepatitis C virus envelope DNA-based immunization elicits humoral and cellular immune responses
41. Optimal induction of hepatitis C virus envelope-specific immunity by bicistronic plasmid DNA inoculation with the granulocyte-macrophage colony-stimulating factor gene
42. Nucleic acid vaccines against hepatitis viruses
43. Modulation of immune responses to hepatitis C virus envelope E2 protein following injection of plasmid DNA using single or combined delivery routes
44. Expression of noncovalent hepatitis C virus envelope E1-E2 complexes is not required for the induction of antibodies with neutralizing properties following DNA immunization
45. DNA immunization of mice and macaques with plasmids encoding hepatitis C virus envelope E2 protein expressed intracellularly and on the cell surface
46. Vaccination of chimpanzees with plasmid DNA encoding the hepatitis C virus (HCV) envelope E2 protein modified the infection after challenge with homologous monoclonal HCV
47. Heterologous and homologous protection against influenza A by DNA vaccination: Optimization of DNA vectors
48. Structure and organization of the hepatitis C virus genome isolated from human carriers
49. Secretion and purification of hepatitis C virus NS1 glycoprotein produced by recombinant baculovirus-infected insect cells
50. A human monoclonal antibody specific for the N terminus of the hepatitis C virus nucleocapsid protein
51. A method to predict functional residues in proteins
52. A retention signal necessary and sufficient for endoplasmic reticulum localization maps to the transmembrane domain of hepatitis C virus glycoprotein E2
53. Enhancing B and T cell immune response to an HCV E2 DNA vaccine by muscle electro gene transfer
54. Functional characterization of intracellular and secreted forms of a truncated hepatitis C virus E2 glycoprotein
55. Characterization of modified hepatitis C virus E2 proteins expressed on the cell surface
56. Vaccination of chimpanzees with plasmid DNA encoding the hepatitis C virus (HCV) envelope E2 protein modified the infection after challenge with homologous monoclonal HCV
57. T cell recognition of hypervariable region-1 from hepatitis C virus envelope protein with multiple class II MHC molecules in mice and humans: Preferential help for induction of antibodies to the hypervariable region
58. A quantitative test to estimate neutralizing antibodies to the hepatitis C virus: Cytofluorimetric assessment of envelope glycoprotein 2 binding to target cells
59. Immune responses throughout hepatitis C virus (HCV) infection: HCV from the immune system point of view
60. Formation of native hepatitis C virus glycoprotein complexes
61. 1Epitope mapping of antibodies directed against hypervariable region 1 in acute self-limiting and chronic infections due to hepatitis C virus
62. Construction and characterization of chimeric E2 glycoprotein of hepatitis C virus: Analysis of E2 regions interacting with CD81